 Multi-drug resistance presents a significant problem in the clinical setting and agents that are less susceptible to these mechanisms can successfully be used in prolonged treatment protocols.The DNA modifying agents such as duocarmycin are being used in the development of antibody-drug conjugate or ADCs.Scientists at The Netherlands-based Synthon (formerly Syntarga) have combined a unique linkers with duocarmycin derivatives that have a hydroxyl group which is crucial for biological activity.